Medifast, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2027: Daniel R. Chard

Medifast, Inc.’s own tally for this item (“Elect Director: Daniel R. Chard”): 4,377,045 for, 261,811 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Accordingly, each of the individuals listed above was elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 2,035,836 for, 1,285 against.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2027: Elizabeth A. Geary

Medifast, Inc.’s own tally for this item (“Elect Director: Elizabeth A. Geary”): 4,313,878 for, 323,551 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Accordingly, each of the individuals listed above was elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 1,970,193 for, 66,926 against.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2027: Parsa Kiai

Medifast, Inc.’s own tally for this item (“Elect Director: Parsa Kiai”): 4,378,697 for, 259,279 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Accordingly, each of the individuals listed above was elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 2,037,120 for.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2027: Jeffrey Rose

Medifast, Inc.’s own tally for this item (“Elect Director: Jeffrey Rose”): 4,398,976 for, 238,929 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Accordingly, each of the individuals listed above was elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 2,037,120 for.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2027: Scott Schlackman

Medifast, Inc.’s own tally for this item (“Elect Director: Scott Schlackman”): 3,842,303 for, 795,603 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Accordingly, each of the individuals listed above was elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 1,604,324 for, 432,797 against.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2027: Andrea B. Thomas

Medifast, Inc.’s own tally for this item (“Elect Director: Andrea B. Thomas”): 4,260,999 for, 378,012 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Accordingly, each of the individuals listed above was elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 1,935,293 for, 101,828 against.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Elect seven nominees to the Board of Directors to serve for a one-year term expiring in 2027: Ming Xian

Medifast, Inc.’s own tally for this item (“Elect Director: Ming Xian”): 4,275,817 for, 356,337 against, per its Form 8-K filed May 26, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Accordingly, each of the individuals listed above was elected to the Company's Board of Directors, each to hold office until the Company's next annual meeting of stockholders and until his or her successor is duly elected and qualified, or until his or her earlier death, resignation or removal.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 1,968,908 for, 68,213 against.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Approve the Amended and Restated 2012 Share Incentive Plan.

Medifast, Inc.’s own tally for this item (“(iv) The stockholders voted on a proposal to approve the Amended 2012 Plan.”): 3,195,078 for, 1,442,997 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal was approved by a vote of the stockholders as follows:”
Support: 69% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 1,187,273 for, 849,848 against.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

Description as filed by funds: Approve, on an advisory basis, the compensation of the Company's named executive officers.

Medifast, Inc.’s own tally for this item (“(iii) The stockholders voted on a proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as set forth in the proxy statement for the Annual Meeting.”): 3,996,046 for, 637,173 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal was approved by a vote of the stockholders as follows:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 45 managers: 1,739,668 for, 297,427 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 112 managers: 2,854,628 for, 360,599 against, 185 abstained. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: Ratify the appointment of RSM US LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.

Medifast, Inc.’s own tally for this item (“(ii) The stockholders voted on a proposal to ratify the appointment of RSM US LLP as the Company's Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026.”): 6,411,175 for, 53,444 against — passed, per its Form 8-K filed May 26, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The proposal was approved by a vote of stockholders as follows:”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 47 asset managers below reported 2,037,120 for.

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.